Long-term health-related quality of life after curative treatment for prostate cancer: A regional cross-sectional comparison of two standard treatment modalities

Hjälm-Eriksson,Marie; Lennernäs,Bo; Ullén,Anders; Johansson,Hemming; Hugosson,Jonas; Nilsson,Sten; Brandberg,Yvonne

doi:10.3892/ijo.2014.2734

Long-term health-related quality of life after curative treatment for prostate cancer: A regional cross-sectional comparison of two standard treatment modalities

Authors:
- Marie Hjälm-Eriksson
- Bo Lennernäs
- Anders Ullén
- Hemming Johansson
- Jonas Hugosson
- Sten Nilsson
- Yvonne Brandberg
View Affiliations

Affiliations: Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden, Jubileumskliniken, Sahlgrenska University Hospital, Gothenburg, Sweden, Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden
Published online on: October 29, 2014 https://doi.org/10.3892/ijo.2014.2734
Pages: 381-388

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effects on long-term health-related quality of life (HRQoL) were evaluated in patients treated for localized prostate cancer by two standard modalities: radical retropubic prostatectomy (RP) and external beam radiotherapy combined with a high-dose-rate brachytherapy boost (HDRBT-EBRT). The HRQoL data were compared with age-adjusted normative data. Men diagnosed with localized prostate cancer and treated with curative intent in Gothenburg, Sweden, 1988-1997 were included. HRQoL was measured in October 2000 using the EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires, with a response rate of 82% (n=347). No differences in patient characteristics were found between the two treatment groups, except regarding tumor stage and PSA recurrence at the time of the questionnaires. In the RP group, 42% had T1 and 6% had T3-4 tumors; corresponding proportions in the HDRBT-EBRT group were 29% and 13% (p=0.01). PSA recurrence was detected in 44% of RP patients and 9% of HDRBT-EBRT patients. In most domains, mean HRQoL scores were high and similar to the scores for the age-adjusted normative sample. However, patients reported better role and physical function compared to the normal population. We also observed more sleeping disturbances but less pain among patients than in the normal population. The disease-specific questionnaires showed statistically significant higher levels of bowel and urinary problems in the irradiated group than in the RP group, and the absolute difference between the groups was small and had minor clinical significance. We conclude that overall the general quality of life was rated high by the patients irrespective of curative treatment modality and in agreement with age-adjusted normative data. Statistically significant differences in bowel and urinary symptoms were found between the two treatment groups in favor of the RP group, but the clinical significance was small.

View Figures

View References

1	Grimm P, Billiet I, Bostwick D, et al: Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 109(Suppl 1): 22–29. 2012. View Article : Google Scholar
2	Frank SJ, Pisters LL, Davis J, et al: An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol. 178:2151–2156. 2007. View Article : Google Scholar : PubMed/NCBI
3	Wei JT, Dunn RL, Sandler HM, et al: Comprehensive comparison of healthrelated quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 20:557–566. 2002. View Article : Google Scholar : PubMed/NCBI
4	Namiki S and Arai Y: Health-related quality of life in men with localized prostate cancer (Rewiev). Int J of Urol. 17:125–138. 2010. View Article : Google Scholar : PubMed/NCBI
5	Viani GA, da Silva LG and Stefano EJ: High-dose conformal radiotherapy reduces prostate cancer-specific mortality: results of a meta-analysis. Int J Radiat Oncol Biol Phys. 83:e619–e625. 2012. View Article : Google Scholar
6	Vordermark D, Wulf J, Markert K, et al: 3-D conformal treatment of prostatecancer to 74 Gy vs. high-dose-rate brachytherapy boost: a cross-sectional quality-of-life survey. Acta Oncol. 45:708–716. 2006. View Article : Google Scholar : PubMed/NCBI
7	Joseph KJ, Alvi R, Skarsgard D, et al: Analysis of health related quality of life of patients with clinically localized prostate cancer, one year after treatment with external beam radiotherapy (EBRT) alone versus EBRT and high dose rate brachytherapy. Radiat Oncol. 3:202008.PubMed/NCBI
8	American Joint Committee on Cancer. Manual for Staging of Cancer. 4th edition. Lippincott Raven; Philadelphia: 1992
9	Grenabo L, Grundtman S and Hedelin H: Laparoscopic obturator lymph node dissection in patients with prostatic cancer. Scand J Urol Nephrol. 29:51–55. 1995. View Article : Google Scholar : PubMed/NCBI
10	Lennernäs B, Rikner G, Letocha H, et al: External beam radiotherapy of localized prostatic adenocarcinoma. Acta Oncol. 34:953–958. 1995.PubMed/NCBI
11	Hugosson J, Abrahamsson PA, Ahlgren G, et al: The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. Eur Urol. 29:413–419. 1996.
12	Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 85:365–376. 1993. View Article : Google Scholar : PubMed/NCBI
13	Van Andel G, Bottomley A, Fosså SD, et al: An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 44:2418–2424. 2008.
14	Fayers P, Aaronson N, Bjordahl K, et al: The EORTC QLQ-C30 scoring Manual. 3rd edition. European Organization for Cancer Research and Treatment of Cancer; Brussels: 2001
15	Michelson H, Bolund C, Nilsson B, et al: Health-related quality of life measured by the EORTC QLQ-C30 - reference values from a large sample of Swedish population. Acta Oncol. 39:477–484. 2000. View Article : Google Scholar : PubMed/NCBI
16	Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health related quality-of-life scores. J Clin Oncol. 16:139–144. 1998.PubMed/NCBI
17	Hoffman RM, Gilliland FD, Penson DF, et al: Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer. 101:2011–2019. 2004. View Article : Google Scholar
18	Litwin MS, Gore JL, Kwan L, et al: Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 109:2239–2247. 2007. View Article : Google Scholar : PubMed/NCBI
19	Sanda MG, Dunn RL, Michalski J, et al: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 358:1250–1261. 2008. View Article : Google Scholar : PubMed/NCBI
20	Potosky AL, Davis WW, Hoffman RM, et al: Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 96:1358–1367. 2004.PubMed/NCBI
21	Wahlgren T, Nilsson S, Lennernäs B and Brandberg Y: Promising long-term health related quality of life after high-dose-rate brachytherapy boost for localized prostate cancer. Int J Radiat Oncol Biol Phys. 69:662–670. 2007. View Article : Google Scholar : PubMed/NCBI
22	Sprangers MAG and Schwartz CE: Integrating response shift into health-related quality of life research: a theoretical model. Soc Sci Med. 48:1507–1515. 1999. View Article : Google Scholar : PubMed/NCBI